AVEO Pharmaceuticals, Inc. (AVEO)

[Biotech Pharmer]

Yes. Looks like the expired options were holding her back. I see your 20% pop with positive futility analysis results, and likely not much more than that. I think the market has already assumed it. We need news from NVS on AV-380. That is the missing link and a potentially huge revenue influx at this point....unless NVS is looking for a sensible alternative to milestone payments. BTW, they have deep pockets.